68
Participants
Start Date
January 11, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
May 31, 2026
T3011 high dose
T3011 high dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W
T3011 middle dose
T3011 middle dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W
T3011 low dose
T3011 low dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W
RECRUITING
Anyang Cancer Hospital, Anyang
RECRUITING
The First Affiliated Hospital of Bengbu Medical University, Bengbu
RECRUITING
Hunan cancer hospital, Changsha
RECRUITING
Sichuan Cancer Hospital, Chengdu
RECRUITING
Dongguan People's Hospital, Dongwan
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
RECRUITING
The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou
RECRUITING
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
RECRUITING
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
RECRUITING
Harbin Medical University Cancer Hospital, Ha’erbin
RECRUITING
Shandong cancer hospital, Jinan
RECRUITING
Jiangxi cancer hospital, Nanchang
RECRUITING
Guangxi Medical University Affiliated Cancer Hospital, Nanning
RECRUITING
Shanghai East Hospital, Shanghai
RECRUITING
Shanghai Ninth People's Hospital, Shanghai
RECRUITING
Liaoning Cancer Hospital, Shenyang
RECRUITING
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen
RECRUITING
Shanxi Cancer Hospital, Taiyuan
RECRUITING
Tianjin cancer hospital, Tianjin
RECRUITING
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
RECRUITING
Henan cancer hospital, Zhengzhou
Shanghai Pharmaceuticals Holding Co., Ltd
INDUSTRY